Medivation, Inc.

Press Releases

Company News
View Summary Medivation Reports First Quarter 2016 Financial Results
May 5, 2016
PDF 100.5 KB Add to Briefcase
View Summary Medivation Reiterates Rejection of Sanofi's Substantially Inadequate Proposal
May 5, 2016
PDF 18.1 KB Add to Briefcase
View Summary Medivation Announces First Quarter 2016 Financial Results Teleconference on May 5, 2016
May 3, 2016
PDF 11.3 KB Add to Briefcase
View Summary Medivation's Board of Directors Unanimously Rejects Sanofi's Unsolicited Proposal
Apr 29, 2016
PDF 23.1 KB Add to Briefcase
View Summary Medivation Confirms Receipt of Unsolicited Proposal From Sanofi
Apr 28, 2016
PDF 11.0 KB Add to Briefcase
View Summary Medivation Announces Participation at Upcoming Investor Conferences
Apr 27, 2016
PDF 11.2 KB Add to Briefcase
View Summary Medivation Announces First Quarter 2016 Financial Results Teleconference on May 5, 2016
Apr 21, 2016
PDF 9.0 KB Add to Briefcase
View Summary Medivation Announces Presentation of Phase 2 Enzalutamide Data Evaluating Potential Immune-Activating Properties in Non-Metastatic Castration Sensitive Prostate Cancer Patients
Apr 20, 2016
PDF 69.7 KB Add to Briefcase
View Summary Medivation Announces Presentation of Phase I Talazoparib Combination Data in Several Advanced Cancers
Apr 17, 2016
PDF 67.6 KB Add to Briefcase
View Summary CHMP Issues Positive Opinion to Include New Data in European Label for XTANDI(R) (Enzalutamide)
Apr 7, 2016
PDF 69.8 KB Add to Briefcase
View Summary Jennifer Jarrett to Join Medivation as Chief Financial Officer
Mar 28, 2016
PDF 12.8 KB Add to Briefcase
View Summary Pivotal Phase III Trial of Enzalutamide Initiated in Metastatic Hormone Sensitive Prostate Cancer
Mar 24, 2016
PDF 338.0 KB Add to Briefcase
View Summary U.S. FDA Lifts Partial Clinical Hold on Medivation's Pidilizumab
Mar 9, 2016
PDF 12.0 KB Add to Briefcase
View Summary Medivation to Present at Barclays Global Healthcare Conference
Mar 1, 2016
PDF 9.2 KB Add to Briefcase
View Summary Medivation Reports Fourth Quarter and Full Year 2015 Financial Results and Provides 2016 Financial Guidance
Feb 25, 2016
PDF 103.6 KB Add to Briefcase
View Summary FDA Accepts for Review Supplemental New Drug Application for XTANDI(R) (enzalutamide) Capsules in Metastatic Castration-Resistant Prostate Cancer With Data From Head-to-Head Studies of Enzalutamide Versus Bicalutamide
Feb 22, 2016
PDF 337.6 KB Add to Briefcase
View Summary Medivation Announces Fourth Quarter and Year-End 2015 Financial Results Teleconference on February 25, 2016
Feb 11, 2016
PDF 9.4 KB Add to Briefcase
View Summary Medivation to Present at Leerink Partners 5th Annual Global Healthcare Conference
Jan 27, 2016
PDF 9.4 KB Add to Briefcase
View Summary Journal of Clinical Oncology Publishes Results From the STRIVE Trial of Enzalutamide Compared to Bicalutamide in Castration-Resistant Prostate Cancer
Jan 26, 2016
PDF 95.4 KB Add to Briefcase
View Summary Lancet Oncology Publishes Results From the Phase 2 TERRAIN Trial of Enzalutamide Compared to Bicalutamide in Metastatic Castration-Resistant Prostate Cancer
Jan 13, 2016
PDF 95.4 KB Add to Briefcase
Showing 1-20 of 368 Page: 1 2 3 4 5 ... 19  Next 20
Add to Briefcase = add release to Briefcase